Honghe Wan - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Honghe Wan

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Bioorganic & Medicinal Chemistry Letters|February 2, 2011

Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3Lalgudi S Harikrishnan, Muthoni G Kamau, Honghe Wan, et al.

ACS Medicinal Chemistry Letters|May 20, 2026

Discovery of BMS-159, an Orally Active Imidazotriazine Pan-CK2 Inhibitor for the Treatment of CancerChristine M Tarby, Amy Hart, Honghe Wan, et al.

ACS Medicinal Chemistry Letters|August 20, 2015

Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative NeoplasmsHonghe Wan, Gretchen M Schroeder, Amy C Hart, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Bioorganic & Medicinal Chemistry Letters|February 2, 2011

Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3Lalgudi S Harikrishnan, Muthoni G Kamau, Honghe Wan, et al.

ACS Medicinal Chemistry Letters|May 20, 2026

Discovery of BMS-159, an Orally Active Imidazotriazine Pan-CK2 Inhibitor for the Treatment of CancerChristine M Tarby, Amy Hart, Honghe Wan, et al.

ACS Medicinal Chemistry Letters|August 20, 2015

Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative NeoplasmsHonghe Wan, Gretchen M Schroeder, Amy C Hart, et al.

Pageof 2